Impact of Rifaximin Therapy on Intestinal Byproducts in End-Stage Renal Disease

Withdrawn before enrolling · Early Phase 1

Conditions studied: End Stage Renal Disease

In brief

The purpose of this study is to determine if rifaximin reduces serum trimethylamine-N-oxide (TMAO) levels in patients with end-stage renal disease.

Key facts

Study ID

NCT02738905

Run by

Jason Stubbs, MD

People needed

0

Starts

2016-01-01

Expected to finish

2019-02-26

Last updated by the study team

2019-02-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of end-stage renal disease
• Receiving chronic intermittent hemodialysis

You may not qualify if…

• Patients with less advanced kidney disease
• Inability or unwillingness to provide informed consent
• Patients who may be pregnant
• Hemodynamically unstable patients
• Patients with liver failure, pancreatic insufficiency, or inflammatory bowel disease
• Patients with ongoing or recent infection and those with history of C-diff infection
• Patients with abnormal bowel structure secondary to surgical or anatomic variations
• Patients on certain medications, including immunosuppressants, antidiarrheal agents, or recent (within the last 2 months) use of antibiotics

Where it is running

• University of Kansas Medical Center — Kansas City, Kansas, United States
• Westwood Dialysis Center — Westwood, Kansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.